Eli Lilly and Company has announced the acquisition of Verve Therapeutics. According to the company announcement Eli Lilly and Company is a global medicine company dedicated to transforming science into healing to improve lives worldwide. With nearly 150 years of pioneering discoveries, Lilly’s medicines currently assist tens of millions globally. The company leverages biotechnology, chemistry, and genetic medicine to address significant health challenges, including redefining diabetes care, treating obesity, combating Alzheimer’s disease, providing solutions for immune system disorders, and transforming difficult-to-treat cancers into manageable conditions. Lilly recently completed its acquisition of Verve Therapeutics, a clinical-stage company specializing in genetic medicines for cardiovascular disease, aiming to advance one-time treatments for individuals at high cardiovascular risk. This acquisition is expected to potentially revolutionize cardiovascular care by offering lifelong risk reduction with a single treatment.

To learn more about Eli Lilly and Company, visit http://www.lilly.com/
Company LinkedIn Page: https://www.linkedin.com/company/eli-lilly-and-company/

Company Contact:

David Ricks, Chief Executive Officer
317-276-2000

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.